• Lead trial counsel for plaintiff Magnolia Medical Technologies in patent litigation brought in the District of Delaware against Kurin, Magnolia’s sole competitor in the field of Initial Specimen Diversion Devices. After a one-week trial, the jury found that Kurin infringed Magnolia’s patent, rejected Kurin’s invalidity defenses, and awarded a 17.7% royalty.
• Lead trial counsel for Pfizer in multiple trade-secret cases, including one that resulted in a TRO and preliminary injunction for Pfizer and another with a substantial global settlement for Pfizer.
• Successfully defended Signify Health against a trade-secret preliminary injunction and other claims by CareCentrix in Delaware federal court.
• Lead trial counsel for Comcast in patent litigations against Rovi in multiple federal district courts, the ITC, the Federal Circuit, and the U.S. Supreme Court in which Rovi asserted 37 patents over four-plus years.
• Defended TSMC against ITC investigation initiated by Innovative Foundry Technologies on five semiconductor foundry patents.
• Prepared ITC complaint for large multinational client accusing competitor of infringing four patents. Received OUII approval for filing shortly before parties entered into a cross license.
• Have advised several clients, from technology multinationals to biopharma startups, as to alleged trade-secret misappropriation by newly hired executives and have overseen related internal investigations.
• As lead trial counsel, secured a permanent injunction and seven-figure verdict for TEK Global in a dispute with competitor Sealant Systems International.*
• As lead trial counsel, successfully defended Netflix and Roku at trial against Rovi in the ITC and in follow-on district-court litigation that resulted in all asserted Rovi patents being found invalid.*
• Represented TSMC against China’s then-leading semiconductor manufacturer, SMIC, in the largest trade-secret case tried to that time, securing a jury verdict on liability for TSMC that prompted a very favorable settlement.*
• Achieved favorable progress for a biopharmaceutical company in a fiduciary-duty and trade-secret litigation that contributed to another biotechnology company acquiring the client for $365 million mid-trial.*

* Selected representations before joining Davis Polk